Work / Animation / Apoptosis and BCL-2
ABT-199/GDC-0199 is a small molecule drug in co-development by Abbvie and Genentech for the selective inhibition of BCL-2, a key regulator of cellular apoptosis. BCL-2, part of the larger BCL-2 family, is responsible for the sequestration of pro-apoptopic proteins along the mitochondrial membrane. Displacement of these proteins from BCL-2 in cancerous cells may prime these cells for apoptosis.
Director of Marketing, Organogenesis
The resulting video was enormously impactful; when we first presented this to our clinicians, their first response was wow and their second response was can I get a copy of that?